# A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection

> **NCT01316237** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 90 (estimated)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** GS-6620
- **DRUG:** GS-6620
- **DRUG:** GS-6620
- **DRUG:** GS-6620
- **DRUG:** GS-6620
- **DRUG:** GS-6620
- **DRUG:** GS-6620 tablet, 450 mg BID
- **DRUG:** GS-6620 tablet
- **DRUG:** GS-6620 tablet

## Key facts

- **NCT ID:** NCT01316237
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2011-10
- **Final completion:** 2012-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2012-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01316237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01316237, "A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01316237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*